ANTG Gets TGA Listing For Cannabis Strain

Australian Natural Therapeutics Group Cannabis

Australian Natural Therapeutics Group (ANTG) has had one its domestically grown cannabis products listed on the Register of Therapeutic Goods (ARTG).

As the name suggests, the Register contains a list of therapeutic goods that can be lawfully supplied in Australia – or exported. The privately held New South Wales based company’s proprietary medicinal cannabis strain, EVE Cannabis Indica, has been listed as suitable for export.

“Our team is pleased to be able to continue to pursue their goal of improving lives through high-quality, pure, effective medicinal cannabis,” said ANTG.

There’s not much in the way of information on the public summary regarding the EVE Cannabis Indica product except that it is dried herb. The summary also indicates 140mg/g, without noting what that is in relation to, for example whether that may refer to tetrahydrocannabinol (THC) or cannabidiol (CBD) levels.

Early in November, the company said it had passed the TGO93 and TGO100 mandatory tests for its first commercial export crop, which specify the standard for quality requirements for medicinal cannabis products (TGO93) and microbiological standards for medicines generally (TGO100).

The ARTG listing would have been very welcome news to the company given its plans. Back in August, the company said it was to commence exports to Germany, where it has inked a 10-year supply deal with Cannamedical Pharma GmbH. ANTG said it expected to see more than two tonnes exported in the first 12 months.

There has been a medical cannabis supply crunch in Germany for quite some time due to domestic cultivation not keeping up with demand resulting from issues with Germany’s tendering processes. Among other Australian cannabusinesses with their sights set on Germany is Little Green Pharma, which exported a medicinal cannabis sample to a company in Germany for product testing back in September.

According to StockHead, ANTG has three production facilities in Australia with a combined area of around 25,000sqm,  plus a manufacturing and research facility in California. One of the Australian facilities is in Armidale, New South Wales. ANTG founder and CEO Matt Cantelo said in August the facility was to see a significant expansion and it move into other products including the production of oils and soft gel capsules. For its extracts, ANTG uses supercriticial CO2 extraction equipment.